Supplemental material
OncoImmunology
Volume 12, 2023 - Issue 1
Open access
4,063
Views
1
CrossRef citations to date
0
Altmetric
Original Research
A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response
Laura Rubio-Péreza Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain;b Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, Spain;c H12O-CNIO Cancer Immunotherapy Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain;d Chair for Immunology UFV/Merck, Universidad Francisco de Vitoria (UFV), Madrid, Spain
https://orcid.org/0000-0002-2877-6092View further author information
Rodrigo Lázaro-Gorinesa Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain;b Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, Spain;c H12O-CNIO Cancer Immunotherapy Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
https://orcid.org/0000-0002-6885-3486View further author information
Seandean L. Harwoode Department of Molecular Biology and Genetics, Aarhus University, Aarhus C, Denmark
https://orcid.org/0000-0003-4654-8832View further author information
Marta Comptef Department of Antibody Engineering, Leadartis SL, QUBE Technology Park, Madrid, Spain
https://orcid.org/0000-0002-7138-9266View further author information
Rocío Navarrof Department of Antibody Engineering, Leadartis SL, QUBE Technology Park, Madrid, Spain
https://orcid.org/0000-0002-0083-7711View further author information
Antonio Tapia-Galisteoa Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain;b Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, Spain;c H12O-CNIO Cancer Immunotherapy Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
https://orcid.org/0000-0002-0507-8435View further author information
Jaume Bonetg Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
https://orcid.org/0000-0001-5210-4387View further author information
Belén Blancoa Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain;b Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, Spain;c H12O-CNIO Cancer Immunotherapy Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
https://orcid.org/0000-0001-5085-7756View further author information
Simon Lykkemarkh Immunotherapy and Cell Engineering Laboratory, Department of Engineering, Aarhus University, Aarhus C, Denmark
https://orcid.org/0000-0001-8920-6926View further author information
Ángel Ramírez-Fernándeza Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain;b Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, Spain;c H12O-CNIO Cancer Immunotherapy Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
https://orcid.org/0000-0002-3265-6878View further author information
Mariola Ferreras-Gutiérrezi Centro de Investigaciones Biológicas Margarita Salas (CIB), CSIC, Madrid, Spain
https://orcid.org/0000-0003-4421-3158View further author information
Carmen Domínguez-Alonsoa Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain;b Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, Spain;c H12O-CNIO Cancer Immunotherapy Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
https://orcid.org/0000-0002-0446-9629View further author information
Laura Díez-Alonsoa Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain;b Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, Spain;c H12O-CNIO Cancer Immunotherapy Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
https://orcid.org/0000-0002-9545-6910View further author information
Alejandro Segura-Tudelaa Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain;b Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, Spain;c H12O-CNIO Cancer Immunotherapy Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
https://orcid.org/0000-0002-5506-0153View further author information
Oana Hangiua Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain;b Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, Spain;f Department of Antibody Engineering, Leadartis SL, QUBE Technology Park, Madrid, SpainView further author information
, Ainhoa Erce-Llamazaresa Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain;b Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, Spain;f Department of Antibody Engineering, Leadartis SL, QUBE Technology Park, Madrid, SpainView further author information
, Francisco J. Blancoi Centro de Investigaciones Biológicas Margarita Salas (CIB), CSIC, Madrid, Spain
https://orcid.org/0000-0003-2545-4319View further author information
Cruz Santosj Faculty of Experimental Sciences, Universidad Francisco de Vitoria (UFV), Madrid, Spain
https://orcid.org/0000-0001-5164-5050View further author information
José L. Rodríguez-Peraltok Department of Pathology, Hospital Universitario 12 de Octubre, Madrid, Spain;l Department of Pathology, Universidad Complutense, Madrid, Spain;m Cutaneous Oncology Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, Spain;n Centro de Investigación Biomédica en Red en Oncología (CIBERONC), Madrid, Spain
https://orcid.org/0000-0002-6578-7153View further author information
Laura Sanzn Centro de Investigación Biomédica en Red en Oncología (CIBERONC), Madrid, Spain;o Molecular Immunology Unit, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
https://orcid.org/0000-0002-3119-3218View further author information
Luis Álvarez-Vallinaa Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain;b Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, Spain;c H12O-CNIO Cancer Immunotherapy Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain;d Chair for Immunology UFV/Merck, Universidad Francisco de Vitoria (UFV), Madrid, SpainCorrespondence[email protected]
https://orcid.org/0000-0003-3053-6757View further author information
Article: 2205336
|
Received 02 Jan 2023, Accepted 17 Apr 2023, Published online: 24 Apr 2023
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.